Table 1.
Susceptibility pattern and antibiotic use metrics.
| Susceptibility Pattern (tested) | Blood n = 22 |
Respiratory n = 142 |
Skin and Soft Tissue n = 105 |
Urine n = 42 |
Others n = 9 |
Average Susceptibility. | Average DDD | Average DOT |
|---|---|---|---|---|---|---|---|---|
| Amikacin (n = 68) | 4 (18%) | 24 (17%) | 25 (24%) | 13 (33%) | 2 (25%) | (24%) | 9.4 | 5.6 |
| Ciprofloxacin (n = 54) | 4 (18%) | 22 (16%) | 18 (18%) | 9 (22%) | 1 (11%) | (17%) | 16.0 | 7.1 |
| Colistin (n = 282) | 21 (100%) | 131 (98%) | 92 (99%) | 30 (100%) | 8 (100%) | (99%) | 2.2 | 9.4 |
| Co-trimoxazole (n = 112) | 3 (14%) | 39 (28%) | 46 (45%) | 22 (56%) | 2 (22%) | (33%) | 6.8 | 7.2 |
| Ceftazidime (n = 57) | 3 (14%) | 21 (15%) | 21 (20%) | 11 (26%) | 1 (11%) | (17%) | 3.3 | 6.0 |
| Gentamycin (n = 58) | 3 (15%) | 21 (16%) | 21 (21%) | 11 (27%) | 2 (22%) | (20%) | 29.5 | 4.5 |
| Meropenem (n = 52) | 3 (14%) | 16 (12%) | 18 (19%) | 15 (41%) | 0 (0%) | (17%) | 6.4 | 7.8 |
| Piperacillin/Tazobactam (n = 58) |
3 (14%) | 22 (15%) | 22 (21%) | 10 (24%) | 1 (11%) | (17%) | 1.3 | 7.0 |
| Tigecycline (n = 180) | 13 (87%) | 90 (85%) | 55 (89%) | 19 (86%) | 3 (75%) | (84%) | 142.3 | 8.0 |
| Doxycycline (n = 73) | 6 (43%) | 25 (40%) | 25 (50%) | 17 (77%) | 0 (0%) | (42%) | 90.0 | 5.7 |
Others: Body fluids and patient-related deceives; DDD: Defined daily dose; DOT: Days of therapy; Average susceptibility = Sum of susceptibility percentages/5.